US 11,890,270 B2
Polymorphic forms of ST-246 and methods of preparation
Shanthakumar R. Tyavanagimatt, Sammamish, WA (US); Melialani A. C. L. S. Anderson, Corvallis, OR (US); William C. Weimers, Corvallis, OR (US); Dylan Nelson, Corvallis, OR (US); Tove' C. Bolken, Keizer, OR (US); Dennis E. Hruby, Albany, OR (US); Michael H. O'Neill, Painesville, OH (US); Gary Sweetapple, Madison, OH (US); and Kelley A. McCloughan, South Haven, MI (US)
Assigned to Siga Technologies, Inc., Corvallis, OR (US)
Filed by Siga Technologies, Inc., Corvallis, OR (US)
Filed on Dec. 29, 2020, as Appl. No. 17/136,674.
Application 17/136,674 is a division of application No. 16/520,897, filed on Jul. 24, 2019, granted, now 10,933,050.
Application 16/520,897 is a division of application No. 16/025,057, filed on Jul. 2, 2018, granted, now 10,406,137, issued on Sep. 10, 2019.
Application 16/025,057 is a division of application No. 15/661,194, filed on Jul. 27, 2017, granted, now 10,045,964, issued on Aug. 14, 2018.
Application 15/661,194 is a division of application No. 14/959,180, filed on Dec. 4, 2015, granted, now 9,744,154, issued on Aug. 29, 2017.
Application 14/959,180 is a division of application No. 13/069,813, filed on Mar. 23, 2011, granted, now 9,339,466, issued on May 17, 2016.
Claims priority of provisional application 61/316,747, filed on Mar. 23, 2010.
Claims priority of provisional application 61/373,031, filed on Aug. 12, 2010.
Prior Publication US 2021/0137885 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/404 (2006.01); A61K 39/275 (2006.01); C07D 209/76 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); C07D 209/70 (2006.01)
CPC A61K 31/404 (2013.01) [A61K 9/1652 (2013.01); A61K 9/4866 (2013.01); A61K 39/275 (2013.01); C07D 209/70 (2013.01); C07D 209/76 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method of treating Orthopoxvirus infections comprising administering to a subject in need thereof a therapeutically effective amount of a polymorph Form I of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide (ST-246) which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2θ of about 7.63, 10.04, 11.47, 14.73, 15.21, 15.47, 16.06, 16.67, 16.98, 18.93, 19.96, 20.52, 20.79, 22.80, 25.16, 26.53, 27.20, 27.60, 29.60, 30.23, 30.49, 30.68, 31.14, 33.65, 34.33, 35.29, 35.56, 36.30, 37.36, 38.42, 38.66 degrees.